12 Small Cap Stocks with High Upside Potential

3. Arcus Biosciences, Inc. (NYSE:RCUS)

Market Capitalization: $841.78 Million

Analyst Upside: 201.89%

No. of Hedge Fund Investors: 35

Arcus Biosciences, Inc. (NYSE:RCUS) is one of the 12 Small Cap Stocks with High Upside Potential. On June 1, Arcus Biosciences presented the first data for casdatifan plus cabozantinib in oral metastatic kidney cancer, which showed a confirmed response.

The trials by Dr. Toni K. Choueiri showed a confirmed overall response rate of 46% in patients who completed a minimum of 12 weeks of follow-up. The trials conducted through casdaifan also included a HIF-2a inhibitor, cabozantinib, a tyrosine kinase inhibitor. The combination had a manageable safety profile with no meaningful overlapping toxicity for the two drugs.

“These data serve as the proof of concept for PEAK-1, which will be initiated in the coming weeks and is designed to generate evidence to change the standard of care for people who have progressed on prior immunotherapy treatment,” said Terry Rosen, Ph.D., chief executive officer of Arcus.

Arcus Biosciences, Inc. (NYSE:RCUS) is working on a broad development program with the immuno-oncology (IO)-naive and post-IO settings with differentiated combinations. This program focuses on maximising the opportunity for casdatifan in clear cell renal cell carcinoma (ccRCC) patients.

Arcus Biosciences, Inc. (NYSE:RCUS) is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer.